CAJ | 학술논문

目的评价健择和氟尿嘧啶(GF)联合适形放疗对局部晚期胰腺痛的疗效.方法前瞻性分析了2002年3月至2006年4月收治的54例局部晚期胰腺癌患者的疗效,其中25例采用GF化疗联合适形放疗(试验组),29例单纯采用GF化疗(对照组).结果试验组和对照组的有效率(CR+PR)分别为69.6%和39.3%(P=0.031 1).远处转移率分别为43.5%和53.6%(P=0.473 1),6个月生存率分别为78.3%和53.6%(P=0.066 4),1年生存率分别为52.2%和25.0%(P=0.045 8);临床获益率(CBR)分别为82.6%和60.7%(P=0.087 7),严重不良事件发生率分别为43.4%和32.1%(P=0.4048).结论健择和氟尿嘧啶联合适形放射治疗局部晚期胰腺癌,在近期有效率、1年生存率方面优于单纯GF化疗,但在临床获益率、远处转移率、6月生存率及严重不良事件方面,二者无明显差异.
목적 평개건택화불뇨밀정(GF)연합괄형방료대국부만기이선통적료효.방법 전첨성분석료2002년3월지2006년4월수치적54례국부만기이선암환자적료효,기중25례채용GF화료연합괄형방료(시험조),29례단순채용GF화료(대조조).결과 시험조화대조조적유효솔(CR+PR)분별위69.6%화39.3%(P=0.031 1).원처전이솔분별위43.5%화53.6%(P=0.473 1),6개월생존솔분별위78.3%화53.6%(P=0.066 4),1년생존솔분별위52.2%화25.0%(P=0.045 8);림상획익솔(CBR)분별위82.6%화60.7%(P=0.087 7),엄중불량사건발생솔분별위43.4%화32.1%(P=0.4048).결론 건택화불뇨밀정연합괄형방사치료국부만기이선암,재근기유효솔、1년생존솔방면우우단순GF화료,단재림상획익솔、원처전이솔、6월생존솔급엄중불량사건방면,이자무명현차이.
Objective To evaluate the effect of combination chemotherapy of gemcitabine and 5-FU plus three dimensional conformal radiotherapy on patients with locally acvanced pancreatic cancer. Methods 54 patients with locally advanced pancreatic cancer from March 2002 to April 2006 were enrolled ,one of 25 pa-tients were treated with combination chemotherapy of GF plus three dimensional conformal radiotherapy (experi-ment group) ,the other 29 patients were treated only with combination chemotherapy of GF (control group). Re-suits The general remission rate(CR + PR) was 69.6% in experiment group and 39.3% in control group (X<2> =4.6471 ,P =0.031 1). There were no statistical difference between the two groups in metastases rates (43.5%vs53.6% ,P =0. 473 1) ,survival rates of six months (78.3% vs53.6% ,P =0.066 4) ,clinical benefit response(82.6% vs60.7% ,P = 0.087 7)and grave adverse events(43.4% vs32.1% ,P = 0.404 8) , but there were sig-nificant difference in survival rates of one year between two groups (53.6% vs25.0% , P = 0.045 8). Conclu-sion Combination chemotherapy of GF plus three dimensional conformal radiotherapy might be better than sin-gle combination chemotherapy of GF in general remission rates and survival rates of twelve months in patients with locally advanced pancreatic cancer,but there were no difference between two groups in clinical benefit re-sponse, metastases rates, survival rates of six months and grave adverse events.